This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

Let's collaborate Boehringer Ingelheim

ISPOR New Orleans, LA, USA, 18-22 May 2019

RETROSPECTIVE CLAIMS ANALYSIS OF TREATMENT DURATION, HEALTH CARE RESOURCE UTILIZATION AND COSTS ASSOCIATED WITH FIRST-LINE TREATMENT OF NSCLC WITH AFATINIB VS. ERLOTINIB IN THE UNITED STATES

Samuelsen C, Lim J, Golembesky AK, Shrestha S, Wang L, Griebsch I

Related Materials

Learn more about the science behind this poster in the videos, papers and other materials below.

Duration of treatment among patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive non-small-cell lung cancer in the USA

Jonathan Lim, Carl Samuelsen, Amanda Golembesky, Sulena Shrestha, Li Wang & Ingolf Griebsch

Related information

About afatinib

A detailed look at afatinib’s mechanism of action and the ErbB Family of receptors that are targeted by afatinib

Afatinib

Afatinib (GIOTRIF®) as monotherapy is approved for the treatment of EGFR TKI-naïve adult patients with locally advanced or metastatic NSCLC with activating EGFR mutation(s); and locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy
Back to top

FOR HEALTHCARE PROFESSIONALS ONLY

image